Patents
Literature
Patsnap Copilot is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Patsnap Copilot

413 results about "Fungating tumour" patented technology

High frequency thermal ablation of cancerous tumors and functional targets with image data assistance

This invention relates to the destruction of pathological volumes or target structures such as cancerous tumors or aberrant functional target tissue volumes by direct thermal destruction. In the case of a tumor, the destruction is implemented in one embodiment of the invention by percutaneous insertion of one or more radiofrequency probes into the tumor and raising the temperature of the tumor volume by connection of these probes to a radiofrequency generator outside of the body so that the isotherm of tissue destruction enshrouds the tumor. The ablation isotherm may be predetermined and graded by proper choice of electrode geometry and radiofrequency (rf) power applied to the electrode with or without temperature monitoring of the ablation process. Preplanning of the rf electrode insertion can be done by imaging of the tumor by various imaging modalities and selecting the appropriate electrode tip size and temperature to satisfactorily destroy the tumor volume. Computation of the correct three-dimensional position of the electrode may be done as part of the method, and the planning and control of the process may be done using graphic displays of the imaging data and the rf ablation parameters. Specific electrode geometries with adjustable tip lengths are included in the invention to optimize the electrodes to the predetermined image tumor size.
Owner:COVIDIEN AG

System for endosurgical removal of tumors by laser ablation with treatment verification - particularly tumors of the prostate

The disclosed invention is a unique, patient-friendly, laser-based tumor ablation system for the removal of malignant tumors of the prostate and, with modified delivery systems, may have application for other areas of the human body.
The disclosed invention is an integrated, robotic treatment subsystem that takes advantage of the capabilities of the previously disclosed MedSci Detection, Mapping and Confirmation System, for the purpose of providing a patient friendly system and method for removing tumors detected by said diagnostic system. The invention is a laser-based endosurgical thermal treatment system that utilizes historical cancer mapping data together with real-time ultrasonic and other data to reliably target and control the eradication of cancer conditions. The system contains computer aided robotic control such that control of the boundary, size, position and orientation of the ablated volume of tissue has a tolerance of less than a millimeter. The disclosed system provides multimodal scanning methods for improved identification and localization of detected tumors, including multi-focal tumors. The disclosed system also provides multiple methods for monitoring the successful progress and conclusion of the treatment. The disclosed system provides the capability of closing the created cavity. The disclosed system resides in a subsystem module and when treatment is to be conducted, the treatment module is substituted in place of the previously disclosed ultrasonic diagnostic module of the MedSci system. The subject thermal treatment system meets the challenges confronting the advancement of thermal treatment systems in the search for a highly effective and patient-friendly cancer treatment.
Owner:MEDSCI TECH INC

Treating or preventing the early stages of degeneration of articular cartilage or subchondral bone in mammals using carprofen and derivatives

Treating or preventing the early stages of degeneration of articular cartilage or subchondral bone in the affected joint of a mammal is accomplished by administering a chondroprotective compound of Formula (I):where A is hydroxy, (C1-C4)alkoxy, amino, hydroxy-amino, mono-(C1-C2)alkylamino, di-(C1-C2)alkylamino; X and Y are independently H or (C1-C2)alkyl; and n is 1 or 2; R6 is halogen, (C1-C3)alkyl, trifluoromethyl, or nitro; R9 is H; (C1-C2)alkyl; phenyl or phenyl-(C1-C2)alkyl, where phenyl is optionally mono-substituted by fluoro or chloro; -C(=O)-R, where R is (C1-C2)alkyl or phenyl, optionally mono-substituted by fluoro or chloro; or -C(=O)-O-R', where R1 is (C1-C2)alkyl.This treatment ameliorates, diminishes, actively treats, reverses or prevents any injury, damage or loss of articular cartilage or subchondral bone subsequent to said early stage of said degeneration. Whether or not a mammal needs such treatment is determined by whether or not it exhibits a statistically significant deviation from normal standard values in synovial fluid or membrane from the affected joint, with respect to at least five of the following substances: increased interleukin-1 beta (IL-1beta); increased tumor necrosis factor alpha (TNFalpha); increased ratio of IL-1beta to IL-1 receptor antagonist protein (IRAP); increased expression of p55 TNF receptors (p55 TNF-R); increased interleukin-6 (IL-6); increased leukemia inhibitory factor (LIF); decreased insulin-like growth factor-1 (IGF-1); decreased transforming growth factor beta (TGFbeta); decreased platelet-derived growth factor (PDGF); decreased basic fibroblast growth factor (b-FGF); increased keratan sulfate; increased stromelysin; increased ratio of stromelysin to tissue inhibitor of metalloproteases (TIMP); increased osteocalcin; increased alkaline phosphatase; increased cAMP responsive to hormone challenge; increased urokinase plasminogen activator (uPA); increased cartilage oligomeric matrix protein; and increased collagenase.
Owner:PFIZER INC +1
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products